Christopher R Sudfeld1, Christopher Duggan2, Said Aboud3, Roland Kupka4, Karim P Manji5, Rodrick Kisenge5, Wafaie W Fawzi6. 1. Departments of Global Health and Population, csudfeld@hsph.harvard.edu. 2. Nutrition, and Division of Gastroenterology and Nutrition, Boston Children's Hospital and Harvard Medical School, Boston, MA; Departments of. 3. Microbiology and Immunology and. 4. Nutrition, and UNICEF Headquarters, New York, NY. 5. Paediatrics and Child Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania; and. 6. Departments of Global Health and Population, Nutrition, and Epidemiology, Harvard School of Public Health, Boston, MA;
Abstract
BACKGROUND:Vitamin D is a potent immunomodulator, but its impact on morbidity and mortality among infants remains unclear. OBJECTIVE: The objective of the study was to prospectively assess the association of vitamin D status with mortality, morbidity, and growth during the first 2 y of life. METHODS: A prospective cohort of 253 HIV-infected and 948 HIV-exposed Tanzanian infants enrolled in a randomized trial of multivitamins (not including vitamin D) was studied. Serum 25-hydroxyvitamin D [25(OH)D] concentrations were measured at 5-7 wk of age and infants were followed at monthly clinic visits until 24 mo. Physicians performed a clinical exam every 3 mo or when an illness was noted. RESULTS:Serum 25(OH)D concentrations were (means ± SDs) 18.6 ± 10.3 ng/mL and 18.1 ± 9.2 ng/mL for HIV-infected and HIV-exposed infants, respectively. Unexpectedly, serum 25(OH)D concentrations ≥30 ng/mL were significantly associated with higher mortality as compared to the 20-29.9 ng/mL reference for HIV-infected (HR: 2.47; 95% CI: 1.13, 5.44; P = 0.02) and HIV-exposed (HR: 4.00; 95% CI: 1.67, 9.58; P < 0.01) infants after multivariate adjustment. We found no statistically significant association between 25(OH)D concentrations <10 ng/mL and mortality for HIV-infected (HR: 1.43; 95% CI: 0.74, 2.78; P = 0.29) and HIV-exposed (HR: 1.56; 95% CI: 0.60, 4.03; P = 0.36) infants. Among HIV-exposed infants, 25(OH)D concentrations ≥30 ng/mL were significantly associated with clinical [incidence ratio rate (IRR): 1.34; 95% CI: 1.06,1.70; P = 0.02] and confirmed (IRR: 1.71; 95% CI: 1.71; 1.15, 2.54; P < 0.01) malaria diagnoses, whereas concentrations of <10 ng/mL were associated with oral candidiasis (IRR: 1.47; 95% CI: 1.00-2.15; P = 0.046) and wasting (HR: 1.71; 95% CI: 1.20, 2.43; P < 0.01). CONCLUSION: The observational design of this study does not allow for causal interpretation; however, the results indicate a strong need for additional studies of vitamin D among HIV-infected and -exposed children, particularly in malaria-endemic settings. The parent trial was registered at clinicaltrials.gov as NCT00197730.
RCT Entities:
BACKGROUND:Vitamin D is a potent immunomodulator, but its impact on morbidity and mortality among infants remains unclear. OBJECTIVE: The objective of the study was to prospectively assess the association of vitamin D status with mortality, morbidity, and growth during the first 2 y of life. METHODS: A prospective cohort of 253 HIV-infected and 948 HIV-exposed Tanzanian infants enrolled in a randomized trial of multivitamins (not including vitamin D) was studied. Serum 25-hydroxyvitamin D [25(OH)D] concentrations were measured at 5-7 wk of age and infants were followed at monthly clinic visits until 24 mo. Physicians performed a clinical exam every 3 mo or when an illness was noted. RESULTS: Serum 25(OH)D concentrations were (means ± SDs) 18.6 ± 10.3 ng/mL and 18.1 ± 9.2 ng/mL for HIV-infected and HIV-exposed infants, respectively. Unexpectedly, serum 25(OH)D concentrations ≥30 ng/mL were significantly associated with higher mortality as compared to the 20-29.9 ng/mL reference for HIV-infected (HR: 2.47; 95% CI: 1.13, 5.44; P = 0.02) and HIV-exposed (HR: 4.00; 95% CI: 1.67, 9.58; P < 0.01) infants after multivariate adjustment. We found no statistically significant association between 25(OH)D concentrations <10 ng/mL and mortality for HIV-infected (HR: 1.43; 95% CI: 0.74, 2.78; P = 0.29) and HIV-exposed (HR: 1.56; 95% CI: 0.60, 4.03; P = 0.36) infants. Among HIV-exposed infants, 25(OH)D concentrations ≥30 ng/mL were significantly associated with clinical [incidence ratio rate (IRR): 1.34; 95% CI: 1.06,1.70; P = 0.02] and confirmed (IRR: 1.71; 95% CI: 1.71; 1.15, 2.54; P < 0.01) malaria diagnoses, whereas concentrations of <10 ng/mL were associated with oral candidiasis (IRR: 1.47; 95% CI: 1.00-2.15; P = 0.046) and wasting (HR: 1.71; 95% CI: 1.20, 2.43; P < 0.01). CONCLUSION: The observational design of this study does not allow for causal interpretation; however, the results indicate a strong need for additional studies of vitamin D among HIV-infected and -exposed children, particularly in malaria-endemic settings. The parent trial was registered at clinicaltrials.gov as NCT00197730.
Authors: Christopher R Sudfeld; Edward L Giovannucci; Sheila Isanaka; Said Aboud; Ferdinand M Mugusi; Molin Wang; Guerino Chalamilla; Wafaie W Fawzi Journal: J Infect Dis Date: 2012-11-16 Impact factor: 5.226
Authors: Mario Fabri; Steffen Stenger; Dong-Min Shin; Jae-Min Yuk; Philip T Liu; Susan Realegeno; Hye-Mi Lee; Stephan R Krutzik; Mirjam Schenk; Peter A Sieling; Rosane Teles; Dennis Montoya; Shankar S Iyer; Heiko Bruns; David M Lewinsohn; Bruce W Hollis; Martin Hewison; John S Adams; Andreas Steinmeyer; Ulrich Zügel; Genhong Cheng; Eun-Kyeong Jo; Barry R Bloom; Robert L Modlin Journal: Sci Transl Med Date: 2011-10-12 Impact factor: 17.956
Authors: Julia L Finkelstein; Saurabh Mehta; Christopher Duggan; Karim P Manji; Ferdinand M Mugusi; Said Aboud; Donna Spiegelman; Gernard I Msamanga; Wafaie W Fawzi Journal: Pediatr Infect Dis J Date: 2012-02 Impact factor: 2.129
Authors: Christopher Duggan; Karim P Manji; Roland Kupka; Ronald J Bosch; Said Aboud; Rodrick Kisenge; James Okuma; Wafaie W Fawzi Journal: Am J Clin Nutr Date: 2012-11-07 Impact factor: 7.045
Authors: Christopher R Sudfeld; Molin Wang; Said Aboud; Edward L Giovannucci; Ferdinand M Mugusi; Wafaie W Fawzi Journal: PLoS One Date: 2012-06-29 Impact factor: 3.240
Authors: Michelle Science; Jonathon L Maguire; Margaret L Russell; Marek Smieja; Stephen D Walter; Mark Loeb Journal: Clin Infect Dis Date: 2013-05-15 Impact factor: 9.079
Authors: Christopher R Sudfeld; Karim P Manji; Emily R Smith; Said Aboud; Rodrick Kisenge; Wafaie W Fawzi; Christopher P Duggan Journal: J Pediatr Gastroenterol Nutr Date: 2017-10 Impact factor: 2.839
Authors: Justin Penner; Rashida A Ferrand; Ceri Richards; Kate A Ward; James E Burns; Celia L Gregson Journal: PLoS One Date: 2018-11-15 Impact factor: 3.240